Education
About Us
Working with TipRanks
Follow Us
Nippon Shinyaku Co., Ltd. (JP:4516)
:4516
4516 Stock Chart & Stats
¥5650.00
-¥42.00(-1.04%)
At close: 4:00 PM EST
¥5650.00
-¥42.00(-1.04%)
Day’s Range― - ―
52-Week Range¥2,967.00 - ¥6,529.00
Previous CloseN/A
Volume198.40K
Average Volume (3M)252.03K
Market Cap
¥330.30B
Enterprise Value¥273.95B
Total Cash (Recent Filing)¥60.77B
Total Debt (Recent Filing)¥4.18B
Price to Earnings (P/E)9.4
Beta0.43
Next Earnings
May 08, 2026EPS Estimate
69.25Next Dividend Ex-DateN/A
Dividend Yield2.12%
Share Statistics
EPS (TTM)149.62
Shares Outstanding70,251,490
10 Day Avg. Volume218,840
30 Day Avg. Volume252,026
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.04
Price to Sales (P/S)1.60
P/FCF Ratio7.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)410.86
Revenue Forecast (FY)¥169.02B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained high gross and net margins indicate durable pricing power and efficient product mix in specialty pharmaceuticals. These margins support reinvestment in R&D and commercialization, enabling continued product lifecycle funding and resilience versus commoditized peers over the next several quarters.
Very Low LeverageExtremely low debt provides strong financial flexibility and reduces refinancing and interest-rate risk. This conservatism enables steady R&D funding, acquisition optionality, and downside protection in cyclical downturns, preserving strategic choices over a multi-quarter horizon.
Strong Cash GenerationHigh conversion of earnings into free cash flow indicates healthy cash generation ability to fund R&D, sustain dividends, and invest in manufacturing. Consistent FCF relative to profits supports long-term capital allocation and reduces reliance on external financing.
Bears Say
Volatile Cash ConversionIntermittent swings in operating cash and slightly negative recent FCF growth point to working-capital or timing risks that can compress available cash for R&D or capital projects. This variability can complicate multi-quarter planning and makes short-term cash outlook less predictable.
Earnings VariabilityWhile margins are healthy, documented year-to-year earnings swings signal exposure to product lifecycle effects, pricing, or demand variability. This makes forecasting mid-term earnings less certain and could challenge consistent EPS progression absent new product drivers.
Moderate ROE Vs PeersROE around 12.7% reflects decent profitability on equity but lags top-tier specialty pharma performers. Over the medium term this may limit relative shareholder return unless company improves R&D productivity or accelerates higher-margin product launches.
Nippon Shinyaku Co., Ltd. News
4516 FAQ
What was Nippon Shinyaku Co., Ltd.’s price range in the past 12 months?
Nippon Shinyaku Co., Ltd. lowest stock price was ¥2967.00 and its highest was ¥6529.00 in the past 12 months.
What is Nippon Shinyaku Co., Ltd.’s market cap?
Nippon Shinyaku Co., Ltd.’s market cap is ¥330.30B.
When is Nippon Shinyaku Co., Ltd.’s upcoming earnings report date?
Nippon Shinyaku Co., Ltd.’s upcoming earnings report date is May 08, 2026 which is in 63 days.
How were Nippon Shinyaku Co., Ltd.’s earnings last quarter?
Nippon Shinyaku Co., Ltd. released its earnings results on Feb 09, 2026. The company reported ¥149.62 earnings per share for the quarter, beating the consensus estimate of ¥70 by ¥79.62.
Is Nippon Shinyaku Co., Ltd. overvalued?
According to Wall Street analysts Nippon Shinyaku Co., Ltd.’s price is currently Overvalued.
Does Nippon Shinyaku Co., Ltd. pay dividends?
Nippon Shinyaku Co., Ltd. pays a Semiannually dividend of ¥62 which represents an annual dividend yield of 2.12%. See more information on Nippon Shinyaku Co., Ltd. dividends here
What is Nippon Shinyaku Co., Ltd.’s EPS estimate?
Nippon Shinyaku Co., Ltd.’s EPS estimate is 69.25.
How many shares outstanding does Nippon Shinyaku Co., Ltd. have?
Nippon Shinyaku Co., Ltd. has 70,251,490 shares outstanding.
What happened to Nippon Shinyaku Co., Ltd.’s price movement after its last earnings report?
Nippon Shinyaku Co., Ltd. reported an EPS of ¥149.62 in its last earnings report, beating expectations of ¥70. Following the earnings report the stock price went up 1.349%.
Which hedge fund is a major shareholder of Nippon Shinyaku Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4516
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Technical Analysis
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Toho Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---